106 related articles for article (PubMed ID: 15820487)
1. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Li QZ; Deng Q; Li JQ; Yi GH; Zhao SP
Clin Chim Acta; 2005 May; 355(1-2):131-6. PubMed ID: 15820487
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Zhao S; Li Q; Liu L; Xu Z; Xiao J
Clin Chim Acta; 2004 Jun; 344(1-2):195-200. PubMed ID: 15149889
[TBL] [Abstract][Full Text] [Related]
3. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
4. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Xie QY; Wang YJ; Sun ZL; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
[TBL] [Abstract][Full Text] [Related]
5. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
6. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
[TBL] [Abstract][Full Text] [Related]
8. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Ke YS; Tao YY; Yang H; Yu GH
Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
11. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. New basic science initiatives with the angiotensin II receptor blocker valsartan.
de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S3-5. PubMed ID: 17199210
[TBL] [Abstract][Full Text] [Related]
14. Single-pill combination of amlodipine and valsartan in the management of hypertension.
Flack JM; Hilkert R
Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
[TBL] [Abstract][Full Text] [Related]
15. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
19. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
Hermida RC; Ayala DE; Khder Y; Calvo C
Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]